Tavaborole
GET
/api/v1/drug/tavaboroleMechanism of action
Sourced from openFDAMechanism-of-action class: Protein Synthesis Inhibitors.
Protein Synthesis
Approval history
Sourced from openFDA- Oct 13, 2020ANDAANDA211297Encube
- Oct 21, 2020ANDAANDA212188Alembic
- Feb 3, 2021ANDAANDA211963Chartwell Rx
- Feb 9, 2021ANDAANDA212224Cipla
- Apr 10, 2023ANDAANDA212294Zydus Lifesciences
FAERS reports
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
55 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
- 1Drug Ineffective916%
- 2Off Label Use47.3%
- 3Cough35.5%
- 4Rash35.5%
- 5Accidental Exposure To Product23.6%
- 6Alopecia23.6%
- 7Asthma23.6%
- 8Death23.6%
- 9Dermatitis Atopic23.6%
- 10Diarrhoea23.6%
- 11Dyspnoea23.6%
- 12Fatigue23.6%
- 13Headache23.6%
- 14Hypersensitivity23.6%
- 15Illness23.6%
Clinical trials
The 10 most recently updated of 11 ClinicalTrials.gov registrations naming Tavaborole as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.
- Cumulative Irritation TestCompleted · Phase 1 · Interventional · 37 enrolled · PfizerNCT00680095updated 2019-04-09
- Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the ToenailCompleted · Phase 3 · Interventional · 604 enrolled · PfizerNCT01302119updated 2019-04-03
- Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the ToenailCompleted · Phase 3 · Interventional · 594 enrolled · PfizerNCT01270971updated 2019-02-22
- Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I)Completed · Phase 2 · Interventional · 15 enrolled · PfizerNCT00680160updated 2019-02-21
- Study of Different Doses of a Novel Treatment for OnychomycosisCompleted · Phase 2 · Interventional · 159 enrolled · PfizerNCT00679965updated 2018-12-12
- Safety and Efficacy Study of Subjects With Onychomycosis of the Great ToenailCompleted · Phase 2 · Interventional · 29 enrolled · PfizerNCT01278394updated 2018-12-06
- Safety and Efficacy Study of Subjects With Onychomycosis of the Great ToenailCompleted · Phase 2 · Interventional · 60 enrolled · PfizerNCT00679523updated 2018-11-14
- An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and AdolescentsCompleted · Phase 4 · Interventional · 55 enrolled · PfizerNCT03405818updated 2018-04-17
- Study of Different Doses of a Novel Treatment for OnychomycosisCompleted · Phase 2 · Interventional · 28 enrolled · PfizerNCT00679770updated 2018-02-20
- Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)Completed · Phase 2 · Interventional · 20 enrolled · PfizerNCT00679601updated 2018-02-20
Frequently asked questions
- How does Tavaborole work?
- Mechanism-of-action class: Protein Synthesis Inhibitors.
- What class of drug is Tavaborole?
- Tavaborole is classified as Other antifungals for topical use, Oxaborole Antifungal, Protein Synthesis Inhibitors, Cellular Synthetic Activity Alteration.
- What are the brand names for Tavaborole?
- Tavaborole is marketed under brand names including Kerydin.
Note. Data for
tavaborole is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.